Literature DB >> 20448206

Cholesterol efflux potential and antiinflammatory properties of high-density lipoprotein after treatment with niacin or anacetrapib.

Laurent Yvan-Charvet1, Jelena Kling, Tamara Pagler, Hongna Li, Brian Hubbard, Tim Fisher, Carl P Sparrow, Andrew K Taggart, Alan R Tall.   

Abstract

OBJECTIVE: To examine the effects of treatments with niacin or anacetrapib (an inhibitor of cholesteryl ester transfer protein) on the ability of high-density lipoprotein (HDL) to promote net cholesterol efflux and reduce toll-like receptor-mediated inflammation in macrophages. METHODS AND
RESULTS: A total of 18 patients received niacin, 2 g/d, for 4 weeks; 20 patients received anacetrapib, 300 mg/d, for 8 weeks; and 2 groups (n=4 and n=5 patients) received placebo. HDL samples were isolated by polyethylene glycol precipitation or ultracentrifugation, tested for the ability to promote cholesterol efflux in cholesterol-loaded THP-I or mouse peritoneal macrophages, or used to pretreat macrophages, followed by lipopolysaccharide exposure. HDL cholesterol levels were increased by 30% in response to niacin and by approximately 100% in response to anacetrapib. Niacin treatment increased HDL-mediated net cholesterol efflux from foam cells, primarily by increasing HDL concentration, whereas anacetrapib treatment increased cholesterol efflux by both increasing HDL concentration and causing increased efflux at matched HDL concentrations. The increased efflux potential of anacetrapib-HDL was more prominent at higher HDL cholesterol concentrations (>12 microg/mL), which was associated with an increased content of lecithin-cholesterol acyltransferase (LCAT) and apolipoprotein E and completely dependent on the expression of ATP binding cassette transporters (ABCA1 and ABCG1). Potent antiinflammatory effects of HDL were observed at low HDL concentrations (3 to 20 microg/mL) and were partly dependent on the expression of ABCA1 and ABCG1. All HDL preparations showed similar antiinflammatory effects, proportionate to the HDL cholesterol concentration.
CONCLUSIONS: Niacin treatment caused a moderate increase in the ability of HDL to promote net cholesterol efflux, whereas inhibition of cholesteryl ester transfer protein via anacetrapib led to a more dramatic increase in association with enhanced particle functionality at higher HDL concentrations. All HDLs exhibited potent ability to suppress macrophage toll-like receptor 4-mediated inflammatory responses, in a process partly dependent on cholesterol efflux via ABCA1 and ABCG1.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20448206      PMCID: PMC2917780          DOI: 10.1161/ATVBAHA.110.207142

Source DB:  PubMed          Journal:  Arterioscler Thromb Vasc Biol        ISSN: 1079-5642            Impact factor:   8.311


  54 in total

Review 1.  Mechanisms of disease: HDL metabolism as a target for novel therapies.

Authors:  Daniel J Rader
Journal:  Nat Clin Pract Cardiovasc Med       Date:  2007-02

2.  Shotgun proteomics implicates protease inhibition and complement activation in the antiinflammatory properties of HDL.

Authors:  Tomas Vaisar; Subramaniam Pennathur; Pattie S Green; Sina A Gharib; Andrew N Hoofnagle; Marian C Cheung; Jaeman Byun; Simona Vuletic; Sean Kassim; Pragya Singh; Helen Chea; Robert H Knopp; John Brunzell; Randolph Geary; Alan Chait; Xue-Qiao Zhao; Keith Elkon; Santica Marcovina; Paul Ridker; John F Oram; Jay W Heinecke
Journal:  J Clin Invest       Date:  2007-03       Impact factor: 14.808

Review 3.  New insights into the role of HDL as an anti-inflammatory agent in the prevention of cardiovascular disease.

Authors:  Philip J Barter; Rajesh Puranik; Kerry-Anne Rye
Journal:  Curr Cardiol Rep       Date:  2007-11       Impact factor: 2.931

Review 4.  Formation of dysfunctional high-density lipoprotein by myeloperoxidase.

Authors:  Stephen J Nicholls; Lemin Zheng; Stanley L Hazen
Journal:  Trends Cardiovasc Med       Date:  2005-08       Impact factor: 6.677

5.  Effect of torcetrapib on the progression of coronary atherosclerosis.

Authors:  Steven E Nissen; Jean-Claude Tardif; Stephen J Nicholls; James H Revkin; Charles L Shear; William T Duggan; Witold Ruzyllo; William B Bachinsky; Gabriel P Lasala; Gregory P Lasala; E Murat Tuzcu
Journal:  N Engl J Med       Date:  2007-03-26       Impact factor: 91.245

6.  Inhibition of cholesteryl ester transfer protein by torcetrapib modestly increases macrophage cholesterol efflux to HDL.

Authors:  Laurent Yvan-Charvet; Fumihiko Matsuura; Nan Wang; Mark J Bamberger; Tu Nguyen; Franz Rinninger; Xian-Cheng Jiang; Charles L Shear; Alan R Tall
Journal:  Arterioscler Thromb Vasc Biol       Date:  2007-02-22       Impact factor: 8.311

7.  Putting cholesterol in its place: apoE and reverse cholesterol transport.

Authors:  Robert W Mahley; Yadong Huang; Karl H Weisgraber
Journal:  J Clin Invest       Date:  2006-05       Impact factor: 14.808

8.  The roles of different pathways in the release of cholesterol from macrophages.

Authors:  Maria Pia Adorni; Francesca Zimetti; Jeffrey T Billheimer; Nan Wang; Daniel J Rader; Michael C Phillips; George H Rothblat
Journal:  J Lipid Res       Date:  2007-08-29       Impact factor: 5.922

9.  Increased lipid rafts and accelerated lipopolysaccharide-induced tumor necrosis factor-alpha secretion in Abca1-deficient macrophages.

Authors:  Masahiro Koseki; Ken-Ichi Hirano; Daisaku Masuda; Chiaki Ikegami; Masaki Tanaka; Akemi Ota; Jose C Sandoval; Yumiko Nakagawa-Toyama; Satoshi B Sato; Toshihide Kobayashi; Yukiko Shimada; Yoshiko Ohno-Iwashita; Fumihiko Matsuura; Iichiro Shimomura; Shizuya Yamashita
Journal:  J Lipid Res       Date:  2006-11-01       Impact factor: 5.922

10.  Effects of torcetrapib in patients at high risk for coronary events.

Authors:  Philip J Barter; Mark Caulfield; Mats Eriksson; Scott M Grundy; John J P Kastelein; Michel Komajda; Jose Lopez-Sendon; Lori Mosca; Jean-Claude Tardif; David D Waters; Charles L Shear; James H Revkin; Kevin A Buhr; Marian R Fisher; Alan R Tall; Bryan Brewer
Journal:  N Engl J Med       Date:  2007-11-05       Impact factor: 91.245

View more
  82 in total

Review 1.  Time to ditch HDL-C as a measure of HDL function?

Authors:  Graziella E Ronsein; Jay W Heinecke
Journal:  Curr Opin Lipidol       Date:  2017-10       Impact factor: 4.776

2.  Changes in lipoprotein subfraction concentration and composition in healthy individuals treated with the CETP inhibitor anacetrapib.

Authors:  Ronald M Krauss; Kathleen Wojnooski; Joseph Orr; J Casey Geaney; Cathy Anne Pinto; Yang Liu; John A Wagner; Julie Mabalot Luk; Amy O Johnson-Levonas; Matt S Anderson; Hayes M Dansky
Journal:  J Lipid Res       Date:  2011-12-17       Impact factor: 5.922

3.  Using bioinformatics and systems genetics to dissect HDL-cholesterol genetics in an MRL/MpJ x SM/J intercross.

Authors:  Magalie S Leduc; Rachael Hageman Blair; Ricardo A Verdugo; Shirng-Wern Tsaih; Kenneth Walsh; Gary A Churchill; Beverly Paigen
Journal:  J Lipid Res       Date:  2012-04-11       Impact factor: 5.922

4.  Clinical trials of HDL cholesterol-raising therapy: what have we learned about the HDL hypothesis from AIM-HIGH?

Authors:  Robert S Rosenson
Journal:  Curr Atheroscler Rep       Date:  2012-06       Impact factor: 5.113

5.  Functions of cholesterol ester transfer protein and relationship to coronary artery disease risk.

Authors:  Alan R Tall
Journal:  J Clin Lipidol       Date:  2010 Sep-Oct       Impact factor: 4.766

6.  Reduction in PCSK9 levels induced by anacetrapib: an off-target effect?

Authors:  Philip J Barter; Fatiha Tabet; Kerry-Anne Rye
Journal:  J Lipid Res       Date:  2015-09-16       Impact factor: 5.922

7.  Paraoxonase-3 is depleted from the high-density lipoproteins of autoimmune disease patients with subclinical atherosclerosis.

Authors:  Judit Marsillach; Jessica O Becker; Tomas Vaisar; Bevra H Hahn; John D Brunzell; Clement E Furlong; Ian H de Boer; Maureen A McMahon; Andrew N Hoofnagle
Journal:  J Proteome Res       Date:  2015-03-13       Impact factor: 4.466

8.  Niacin Therapy Increases High-Density Lipoprotein Particles and Total Cholesterol Efflux Capacity But Not ABCA1-Specific Cholesterol Efflux in Statin-Treated Subjects.

Authors:  Graziella E Ronsein; Patrick M Hutchins; Daniel Isquith; Tomas Vaisar; Xue-Qiao Zhao; Jay W Heinecke
Journal:  Arterioscler Thromb Vasc Biol       Date:  2015-12-17       Impact factor: 8.311

9.  Defining the Safety of Anacetrapib, a CETP Inhibitor, in Patients at High Risk for Coronary Heart Disease: the DEFINE study.

Authors:  Cora E Lewis
Journal:  Curr Cardiovasc Risk Rep       Date:  2011-04

10.  Pegylation of high-density lipoprotein decreases plasma clearance and enhances antiatherogenic activity.

Authors:  Alan R Tall; Nan Wang; Andrew J Murphy; Samuel Funt; Darren Gorman
Journal:  Circ Res       Date:  2013-04-23       Impact factor: 17.367

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.